Are antimicrobial-impregnated catheters effective? When does repetition reach the point of exhaustion?

Clinical Infectious Diseases

Volumn 41, Issue 5, 2005, Pages 681-685

  Crnich, Christopher J ^a   Maki, Dennis G ^a  

^a University of Wisconsin Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; CHLORHEXIDINE; PSEUDOMONIC ACID;

BACTEREMIA; BACTERIUM CULTURE; BLOOD CULTURE; CATHETER INFECTION; CENTRAL VENOUS CATHETER; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; HEMODIALYSIS; HUMAN; IMMUNE DEFICIENCY; INTESTINE MUCOSA; INTRAVASCULAR CATHETER; LENGTH OF STAY; MORTALITY; PRIORITY JOURNAL; REVIEW; SKIN; WOUND DRESSING;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETERIZATION, CENTRAL VENOUS; HUMANS;

EID: 23844434254     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/432620     Document Type: Review

References (65)

1. McConnell SA, Gubbins PO, Anaisse EJ. Are antimicrobial-impregnated catheters effective? Replace the water and grab your washcloth, because we have a baby to wash. Clin Infect Dis 2004; 39:1829-33.
2. Crnich CJ, Maki DG. Are antimicrobial-impregnated catheters effective? Don't throw out the baby with the bathwater. Clin Infect Dis 2004; 38:1287-92.
3. Kennedy HF, Morrison D, Kaufmann ME, et al. Origins of Staphylococcus epidermidis and Streptococcus oralis causing bacteraemia in a bone marrow transplant patient. J Med Microbiol 2000; 49:367-70.
4. Herwaldt LA, Hollis RJ, Boyken LD, Pfeller MA. Molecular epidemiology of coagulase-negative staphylococci isolated from immunocompromised patients. Infect Control Hosp Epidemiol 1992; 13:86-92.
5. Moro ML, Vigano EF, Cozzi Lepri A. Risk factors for central venous catheter-related infections in surgical and intensive care units. The Central Venous Catheter-Related Infections Study Group. Infect Control Hosp Epidemiol 1994; 15:253-64.
6. Mahieu LM, De Muynck AO, Ieven MM, De Dooy JJ, Goossens HJ, Van Reempts PJ. Risk factors for central vascular catheter-associated bloodstream infections among patients in a neonatal intensive care unit. J Hosp Infect 2001; 48:108-16.
7. Crnich CJ, Maki DG. The promise of novel technology for the prevention of intravascular device-related bloodstream infection. I. Pathogenesis and short-term devices. Clin Infect Dis 2002; 34:1232-42.
8. Safdar N, Kluger DM, Maki DG. A review of risk factors for catheter-related bloodstream infection caused by percutaneously inserted, noncuffed central venous catheters: implications for preventive strategies. Medicine 2002; 81:466-79.
9. Safdar N, Maki DG. The pathogenesis of catheter-related bloodstream infection with non-cuffed short-term central venous catheters. Intensive Care Med 2004; 30:62-7.
10. Eggimann P, Harbarth S, Constantin M, Touveneau S, Chevrolet J, Pittet D. Impact of a prevention strategy targeted at vascular-access care on incidence of infections acquired in intensive care. Lancet 2000; 355:1864-8.
11. Sherertz RJ, Ely EW, Westbrook DM, et al. Education of physicians-in-training can decrease the risk for vascular catheter infection. Ann Intern Med 2000; 132:641-8.
12. Maki DG, Ringer M, Alvarado CJ. Prospective randomized trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991; 338:339-43.
13. Chaiyakunapruk N, Veenstra DL, Lipsky BA, Sullivan SD, Saint S. Vascular catheter site care: the clinical and economic benefits of chlorhexidine gluconate compared with povidone iodine. Clin Infect Dis 2003; 37:764-71.
14. Kluger D, Maki D. The relative risk of intravascular device-related bloodstream infections with different types of intravascular devices in adults: a meta-analysis of 206 published studies [abstract]. Infect Control Hosp Epidemiol 2000; 21:95-6.
15. Maki DG, Mermel LA, Kluger DM, et al. The efficacy of a chlorhexidine-impregnated sponge (biopatch) for the prevention of intravascular catheter-related infection: a prospective, randomized, controlled, multicenter trial [abstract 1430]. In: Program and abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto, Ontario). Washington, DC: ASM Press, 2000:422.
16. Sesso R, Barbosa D, Lerne IL, et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheter: effect of mupirocin ointment. J Am Soc Nephrol 1998; 9:1085-92.
17. Ramsay J, Nolle F, Schwarzmann S. Incidence of catheter colonization and catheter-related infection with an antiseptic impregnated triple lumen catheter [abstract]. Crit Care Med 1994; 22:A115.
18. Bach A, Bohrer H, Bottiger B, Motsch J, Martin E. Reduction of bacterial colonization of triple-lumen catheters with antiseptic bonding in septic patients [abstract A261]. Anesthesiology 1994; 81:A261.
19. Trazzera S, Stern G, Rakesh B, Sinna S, Reiser P. Examination of antimicrobial-coated central venous catheters in patients at high-risk for catheter related infections in a medical intensive care unit and leukemia/bone marrow transplant unit [abstract A152]. Crit Care Med 1995; 23:A152.
20. Bach A, Schmidt H, Bottiger B, et al. Retention of antibacterial activity and bacterial colonization of antiseptic-bonded central venous catheters. J Antimicrob Chemother 1996; 37:315-22.
21. Ciresi DL, Albrecht RM, Volkers PA, Scholten DJ. Failure of antiseptic bonding to prevent central venous catheter-related infection and sepsis. Am Surg 1996; 62:641-6.
22. Pemberton LB, Ross V, Cuddy P, Kremer H, Fessier T, McGurk E. No difference in catheter sepsis between standard and antiseptic central venous catheters: a prospective randomized trial. Arch Surg 1996; 131:986-9.
23. van Heerden PV, Webb SA, Fong S, Golledge CL, Roberts BL, Thompson WR. Central venous catheters revisited: infection rates and an assessment of the new Fibrin Analysing System brush. Anaesth Intensive Care 1996; 24:330-3.
24. George SJ, Vuddamalay P, Boscoe MJ. Antiseptic-impregnated central venous catheters reduce the incidence of bacterial colonization and associated infection in immunocompromised transplant patients. Eur J Anaesthesiol 1997; 14:428-31.
25. Logghe C, Van Ossel C, D'Hoore W, Ezzedine H, Wauters G, Haxhe JJ. Evaluation of chlorhexidine and silver-sulfadiazine impregnated central venous catheters for the prevention of bloodstream infection in leukaemic patients: a randomized controlled trial. J Hosp Infect 1997; 37:145-56.
26. Maid DG, Stolz SM, Wheeler S, Mermel LA. Prevention of central venous catheter-related bloodstream infection by use of an antiseptic-impregnated catheter: a randomized, controlled trial. Ann Intern Med 1997; 127:257-66.
27. Raad I, Darouiche R, Dupuis J, et al. Central venous catheters coated with minocycline and rifampin for the prevention of catheter-related colonization and bloodstream infections: a randomized, double-blind trial. Ann Intern Med 1997; 127:267-74.
28. Tennenberg S, Lieser M, McCurdy B, et al. A prospective randomized trial of an antibiotic- and antiseptic-coated central venous catheter in the prevention of catheter-related infections. Arch Surg 1997; 132:1348-51.
29. Heard SO, Wagle M, Vijayakumar E, et al. Influence of triple-lumen central venous catheters coated with chlorhexidine and silver sulfadiazine on the incidence of catheter-related bacteremia. Arch Intern Med 1998; 158:81-7.
30. Collin GR. Decreasing catheter colonization through the use of an antiseptic-impregnated catheter: a continuous quality improvement project. Chest 1999; 115:1632-40.
31. Darouiche RO, Raad, II, Heard SO, et al. A comparison of two antimicrobial-impregnated central venous catheters. N Engl J Med 1999; 340:1-8.
32. Hannan M, Juste RN, Umasanker S, et al. Antiseptic-bonded central venous catheters and bacterial colonisation. Anaesthesia 1999; 54:868-72.
33. Marik PE, Abraham G, Careau P, Varon J, Fromm RE Jr. The ex vivo antimicrobial activity and colonization rate of two antimicrobial-bonded central venous catheters. Crit Care Med 1999; 27:1128-31.
34. Sheng WH, Ko WJ, Wang JT, Chang SC, Hsueh PR, Luh KT. Evaluation of antiseptic-impregnated central venous catheters for prevention of catheter-related infection in intensive care unit patients. Diagn Microbiol Infect Dis 2000; 38:1-5.
35. Hanna H, Benjamin R, Chatzinikolaou I, et al. Long-term silicone central venous catheters impregnated with minocycline and rifampin decrease rates of catheter-related bloodstream infection in cancer patients: a prospective randomized clinical trial. J Clin Oncol 2004; 22:3163-71.
36. Veenstra DL, Saint S, Saha S, Lumley T, Sullivan SD. Efficacy of antiseptic-impregnated central venous catheters in preventing catheter-related bloodstream infection: a meta-analysis. JAMA 1999; 281:261-7.
37. Marin MG, Lee JC, Skurnick JH. Prevention of nosocomial bloodstream infections: effectiveness of antimicrobial-impregnated and heparin-bonded central venous catheters. Crit Care Med 2000; 28:3332-8.
38. Veenstra DL, Saint S, Sullivan SD. Cost-effectiveness of antiseptic-impregnated central venous catheters for the prevention of catheter-related bloodstream infection. JAMA 1999; 282:554-60.
39. Shorr AF, Humphreys CW, Helman DL. New choices for central venous catheters. Chest 2003; 124:275-84.
40. O'Grady NP, Alexander M, Dellinger EP, et al. Guidelines for the prevention of intravascular catheter-related infections. Clin Infect Dis 2002; 35:1281-307.
41. Smith RL, Meixler SM, Simberkoff MS. Excess mortality in critically ill patients with nosocomial bloodstream infections. Chest 1991; 100:164-7.
42. Collignon PJ. Intravascular catheter associated sepsis: a common problem. Med J Australia 1994; 161:374-8.
43. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity and mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol 1999; 20:396-401.
44. Digiovine B, Chenoweth C, Watts C, Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Resp Crit Care Med 1999; 160:976-81.
45. Rello J, Ochagavia A, Sabanes E, et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Resp Crit Care Med 2000; 162:1027-30.
46. Pittet D, Tarara D, Wenzel R. Nosocomial bloodstream infection in critically ill patients: excess length of stay, extra costs, and attributable mortality. JAMA 1994; 271:1598-601.
47. Dimick JB, Pelz RK, Consunji R, Swoboda SM, Hendrix CW, Lipsett PA. Increased resource use associated with catheter-related bloodstream infection in the surgical intensive care unit. Arch Surg 2001; 136:229-34.
48. Renaud B, Brun-Buisson C. Outcomes of primary and catheter-related bacteremia: a cohort and case-control study in critically ill patients. Group IC-BS. Am J Resp Crit Care Med 2001; 163:1584-90.
49. McConnell SA, Gubbins PO, Anaisse EJ. Do antimicrobial-impregnated central venous catheters prevent catheter-related bloodstream infection? clin Infect Dis 2003; 37:65-72.
50. Crnich CJ, Maki DG. The role of intravascular devices in sepsis. Curr Infect Dis Rep 2001; 3:496-506.
51. Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections, 1988. Am J Infect Control 1988; 16:128-40.
52. Wingard JR, White MH, Anaissie E, et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31:1155-63.
53. Walsh TJ, Pappas P, Winston DJ, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med 2002; 346:225-34.
54. Rothman KJ, Greenland S. Precision and validity in epidemiologic studies. In: Modern epidemiology. Philadelphia: Lippincott-Raven, 1998:115-34.
55. Walsh TJ, Hiemenz JW, Seibel NL, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
56. Bernard GR, Vincent J-L, Laterre P-F, et al. Efficacy and safety of recombinant human activated protein C for severe sepsis. N Engl J Med 2001; 344:699-709.
57. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphoterici n B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347:408-15.
58. Safdar N, Maki DG. The risk of cather-related bloodstream infection with peripherally-inserted central venous catheeters used in inpatients [abstract K-1435]. In: Program and abstracts of the 41st International Conference of Antimicrobial Agents and Chemotherapy (Chicago, Illinois). Washington, DC: ASM Press, 2001:428.
59. Safdar N, Maki DG. The incidence and pathogenesis of catheter-related bloodstream infection with arterial catheters [abstract K-81]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego, California). Washington, DC: ASM Press, 2002:299.
60. Cook D, Randolph A, Kernerman P, et al. Central venous catheter replacement strategies: a systematic review of the literature. Crit Care Med 1997; 25:1417-24.
61. Anaissie EJ, Penzak SR, Dignani MC. The hospital water supply as a source of nosocomial infections: a plea for action. Arch Intern Med 2002; 162:1483-92.
62. Costa SF, Miceli M, Anaisse EJ. Mucosa or skin as source of coagulase-negative staphylococcal bacteremia. Lancet Infect Dis 2004; 4:278-86.
63. The Bacteriology and Mycology Study Group. Available at: http://www.niaid.nih.gov/dmid/ antimicrob.html. Accessed 28 January 2005.
64. Kuhn TS. The structure of scientific revolutions. 2nd ed. Chicago: University of Chicago Press, 1962.
65. Berenholtz SM, Pronovost PJ, Lisett PA, et al. Eliminating catheter-related bloodstream infection in the intensive care unit. Crit Care Med 2004; 32:2014-20.